Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
Trial ID or NCT#
This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64 years) undergoing allogeneic hematopoietic cell transplantation (HCT) for myelodysplastic syndromes (MDS).
A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study
- In order to be eligible to participate on this study, an individual must meet all of the following criteria: 1. Underwent an allogeneic HCT for MDS on the 10-CMSMDS-1 protocol 2. Prior consent to research and future contact by the CIBMTR 3. Ability to provide RCI BMT protocol 17-ePRO signed and dated informed consent form (ICF) 4. Age ≥55 years at time of transplant 5. Fluent in English or Spanish 6. Greater than 6 months post-HCT
- An individual who meets any of the following criteria will be excluded from participation on this study. 1. No access to an internet browser or email account 2. Within 6 months of first HCT for MDS on the 10-CMSMDS-1 protocol
Contact us to find out if this trial is right for you.
Michelle Chin, MS